With the advent of targeted therapies, treatment outcomes for patients with HER2-positive BC have significantly improved, resulting in a 7-year disease-free survival rate of 93.3% (Romond et al. 2005; Tolaney et al. 2019). The gene discussed is ERBB2; the disease is breast cancer.